Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. The biggest battle arena by far is oncology. oncology therapeutics market has reached $71 billion. oncology therapeutics market has reached $71 billion. ” The U.S.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

pharmaphorum

JANUARY 11, 2021

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market. Meanwhile the as-yet unnamed oncology company will spin off under the leadership of bluebird’s current chief executive Nick Leschly. million price tag.

Gene Therapy 66

Gene Therapy Gene Genetic Disease Manufacturing 66

The Pharma Data

AUGUST 18, 2020

The investigational therapy has obviously caught the eye of BMS, and it was confirmed that the company intends to exercise its newly bought rights to push the drug forward in oncology and haematology.

Protein 52

Protein Sales Drugs 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. Immunocore received Breakthrough Device Designation for Kimmtrak from the FDA in February 2021 followed by acceptance of its Biologics License Application (BLA) several months later by both US and European regulators.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

Drug Discovery World

JANUARY 10, 2023

Our catalog of over 6,500+ primary antibodies, 1,200+ secondary antibodies, and 50+ ELISA kits includes reagents for multiplex IF, flow cytometry, and more in fields including immunology, oncology, and neuroscience. Pillar 5: Protein OE/Epitope Tags. Antibody validation. Pillar 4: Biological Characteristics.

Antibody 52

Antibody Protein Reagent Scientist 52